Cilostazol Mitigates Diabetes Induced Neuropathy and Peripheral Arterial Disease
Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 30, 2024 3 days, 5 hours, 23 minutes ago
Medical News: A Breakthrough for Diabetes Complications
Diabetes mellitus, a chronic condition affecting millions globally, often brings severe complications over time. Two of the most burdensome are peripheral arterial disease (PAD) and diabetic neuropathy, both of which significantly impair quality of life. Researchers from the Hospital Evangélico de Londrina in Brazil, Pontifícia Universidade Católica do Paraná, and New York University have been exploring a promising treatment option – cilostazol - to mitigate these conditions.
Cilostazol Mitigates Diabetes Induced Neuropathy and Peripheral Arterial Disease
Cilostazol, a phosphodiesterase-3 inhibitor, has shown efficacy in treating intermittent claudication associated with PAD, enhancing blood flow and walking distance for patients. More recently, its potential to address diabetic neuropathy has sparked interest. This
Medical News report delves into the mechanisms, findings, and implications of using cilostazol to combat these debilitating diabetes complications.
Understanding the Challenges of Diabetic Neuropathy and PAD
Diabetic neuropathy stems from prolonged hyperglycemia, leading to nerve damage characterized by pain, loss of sensation, and, eventually, motor dysfunction. Simultaneously, diabetes heightens the risk of PAD, a condition where reduced blood flow to limbs causes pain during physical activity - a phenomenon known as claudication. Together, these conditions severely limit mobility and overall quality of life for patients.
Over 425 million adults worldwide were living with diabetes in 2017, a figure projected to climb to 629 million by 2045. Among them, nearly half may experience diabetic neuropathy, while PAD is alarmingly common among aging diabetic populations. Addressing these complications is not just a medical necessity but also an economic imperative, as the cost of diabetes management - including related complications - exceeded $850 billion globally in 2017.
Cilostazol’s Mechanisms and Early Findings
Cilostazol operates by inhibiting phosphodiesterase-3A, leading to increased levels of cyclic adenosine monophosphate (cAMP) in cells. This action promotes vasodilation, platelet inhibition, and enhanced blood flow. In diabetic neuropathy, cilostazol’s effects extend to improving nerve conduction and potentially aiding in nerve regeneration.
Experimental studies have demonstrated cilostazol’s ability to enhance motor nerve conduction, restore nerve fiber density, and increase blood flow to peripheral nerves. In animal models, cilostazol improved nerve conduction velocity and alleviated hypoxia-related damage by boosting nitric oxide production and cAMP levels. These findings suggest that cilostazol may counteract both ischemic and inflammatory pathways involved in diabetic neuropathy.
Clinical Studies: Mixed Results
Despite promising preclinical evidence, human trials have yielded varied outcomes. In one
study, patients with diabetic neuropathy received either a placebo or cilostazol at 100 mg or 200 mg daily for 12 weeks. While improvements in neuropathy symptom scores were noted, the differences between treatment groups were not statistically significant. This highlights the need for longer trials with larger populations to ascertain cilostazol’s efficacy in managing diabetic neuropathy.
Conversely, cilostazol’s benefits in PAD are well-documented. The drug has consistently shown the ability to increase pain-free and maximum walking distances for patients with intermittent claudication. By improving blood flow to the lower limbs, cilostazol alleviates symptoms and enhances physical activity levels, a critical factor in diabetes management.
Implications for Diabetes Care
The dual action of cilostazol - improving vascular health and potentially aiding nerve function - positions it as a unique therapeutic option for diabetic patients facing multiple complications. However, its efficacy in diabetic neuropathy remains uncertain, underscoring the need for more robust clinical studies. Researchers emphasize the importance of standardized treatment protocols and longer follow-up periods to better understand cilostazol’s impact.
Conclusion
Cilostazol offers a beacon of hope for patients grappling with the intertwined complications of diabetes. Its proven benefits in managing PAD and potential to improve diabetic neuropathy make it a valuable addition to the diabetes care arsenal. However, the path forward demands rigorous research to overcome inconsistencies in clinical findings. With well-designed trials and a focus on optimizing treatment regimens, cilostazol could play a pivotal role in enhancing outcomes for diabetic patients worldwide.
The study findings were published in the peer-reviewed journal: Medical Sciences.
https://www.mdpi.com/2076-3271/13/1/1
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/leg-pain-can-be-signs-of-peripheral-artery-disease-especially-in-men
https://www.thailandmedical.news/news/cardiology-canadian-study-shows-that-combo-of-xarelto-with-aspirin-more-effective-to-treat-patients-with-cardiovascular-or-peripheral-arterial-disease
https://www.thailandmedical.news/news/u-s-study-finds-that-cannabis-users-are-three-times-more-likely-to-develop-peripheral-artery-disease
https://www.thailandmedical.news/articles/diabetes
Share
Tweet
Share
